Mesoblast’s Ryoncil Wins FDA Approval for Rare Children’s Disease
Mesoblast, a biotech company, secured US Food and Drug Administration (FDA) approval for its first-ever treatment for children with graft versus host disease (GVHD). The stock surged over 35% to $16.61 in afternoon trades, with analysts predicting strong growth and potential revenue of up to $500 million. GVHD is a common complication following bone-marrow transplants, … Read more